Medullary thyroid cancer (MTC) is a rare type of thyroid cancer that develops from the parafollicular C cells of the thyroid gland which produce calcitonin. MTC accounts for about 3–5% of all thyroid cancers. Symptoms include a lump in the neck, swelling in the neck or hoarseness. Conventional therapies such as surgery, radiation therapy and chemotherapy are often ineffective in treating advanced or metastatic MTC. Recent clinical trials have demonstrated promising results of targeted therapies like vandetanib, cabozantinib and lenvatinib against MTC.
The medullary thyroid cancer drugs market is estimated to be valued at USD 156 Mn in 2024 and is expected to reach USD 315 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031.
Key Takeaways
Key players operating in the medullary thyroid cancer drugs are AstraZeneca, Exelixis Inc. and Bristol-Myers Squibb Company.
The promising results demonstrated by targeted drugs in clinical trials present lucrative opportunities for market players to expand their drug portfolio and gain more approvals. Further research focusing on combination therapies and novel drug targets hold potential to strengthen the treatment landscape.
North America dominates the global Medullary Thyroid Cancer Drugs Market owing to large patient pool and rapid adoption of newly approved therapies. However, Asia Pacific is expected to exhibit fastest growth during the forecast period with increasing incidence of thyroid cancer and focus on development of healthcare infrastructure in emerging economies.
Market Drivers
The robust drug pipeline with novel targeted therapies in different clinical trial phases is the major factor driving the growth of medullary thyroid cancer drugs market. Drugs like sunitinib, sorafenib, pazopanib and selpercatinib have potential to address the unmet needs. Further, the rising public health awareness programs and initiatives by government and pharma companies to spread education about rare cancers are supporting early detection and management of MTC, thereby boosting the market growth.
PEST Analysis
Political: Government policies and regulations related to drug approval and clinical trials affects the market. Restrictions on certain therapies can hamper market growth.
Economic: High healthcare spending and rising disposable incomes in developed nations supports market growth. However, economic slowdowns could negatively impact adoption of high-cost drugs.
Social: Increasing awareness about early diagnosis and treatment of rare cancers through social media and patient advocacy groups influences the market.
Technological: Advancements in targeted drug therapies, molecular diagnostics, and precision medicine are transforming the treatment landscape and expanding options for patients. Development of companion diagnostics also facilitates patient selection.
Geographical Regions of Concentration
North America currently accounts for the largest share of the global medullary thyroid cancer drugs market in terms of value. This is attributed to the presence of well-developed healthcare systems, high healthcare expenditure, product accessibility, and growing disease awareness in the region. The United States dominates the North American as well as global market.
Fastest Growing Regional Market
The Asia Pacific medullary thyroid cancer drugs market is expected exhibit the fastest growth over the forecast period supported by increasing healthcare spending of countries, expansions of key players, and growing patient population in developing nations. Rising incidences, growing penetration of advanced therapies, and improving access to diagnosis and treatment in populous nations such as China and India will boost the APAC market during the analysis timeline.
Get This Report in Japanese Language: 甲状腺髄様がん治療薬市場
Get This Report in Korean Language: 수질성 갑상선 암 약물 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
